Onyx starts multiple myeloma trial; OncoMed brings 100 jobs to Buffalo, NY;

 @FierceBiotech: Lilly CEO: Pipeline to soften patent losses. Report | Follow @FierceBiotech

> The International Stem Cell Corporation has received $10 million of funding from ARG Vermogensverwaltung. The funding will be used to create ISCO Europe, and shares will trade independently from its U.S. parent company. Release

> OncoMed is coming to Buffalo Niagara Medical Campus for bio-oncology and pharmacy care, bringing 100 jobs in two years to its new 4,500 square foot residence. Story

> Fera Pharmaceuticals has acquired a new orphan drug, Itraconazole for fungal otitis externa. Itraconazole has completed a Phase II pilot study which found no adverse effects to the drug. Item

> Onyx Pharmaceuticals has started enrolling patients into its Phase III ASPIRE trial. The trial tests carfilzomib with lenalidomide and dexamethasone for multiple myeloma patients. Release

And Finally... People with high levels of the so-called good cholesterol HDL tend to have fewer heart attacks, but HDL may offer little protective benefit in people who take statins to lower harmful LDL cholesterol, U.S. researchers say. Report

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.

VBL got the green light after the committee looked at unblinded overall survival data for the second pre-planned interim analysis.